Design of the randomized, Phase III, QUAZAR AML Maintenance trial of CC-486 (oral azacitidine) maintenance therapy in acute myeloid leukemia

Older patients with acute myeloid leukemia (AML) have worse rates of complete remission and shorter overall survival than younger patients. The epigenetic modifier CC-486 is an oral formulation of azacitidine with promising clinical activity in patients with AML in Phase I studies. The Phase III, ra...

Descrición completa

Gardado en:
Detalles Bibliográficos
Publicado en:Future Oncol
Main Authors: Roboz, Gail J, Montesinos, Pau, Selleslag, Dominik, Wei, Andrew, Jang, Jun-Ho, Falantes, Jose, Voso, Maria T, Sayar, Hamid, Porkka, Kimmo, Marlton, Paula, Almeida, Antonio, Mohan, Sanjay, Ravandi, Farhad, Garcia-Manero, Guillermo, Skikne, Barry, Kantarjian, Hagop
Formato: Artigo
Idioma:Inglês
Publicado: Future Medicine Ltd 2016
Assuntos:
Clinical Trial Protocol
Acceso en liña:https://ncbi.nlm.nih.gov/pmc/articles/PMC5684733/
https://ncbi.nlm.nih.gov/pubmed/26785287
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2217/fon.15.326
Tags: Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!

Títulos similares